Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
VolitionRx is growing its money very fast and testing new medical tools in more areas of healthcare. Watch whether doctors and hospitals actually start using these new tools, since that's what will really matter for the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.